ENTA Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc. (ENTA) is expected to report earnings on November 9, 2026, after the market close. The consensus earnings estimate is a loss of $0.63 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -4.2% since its last earnings release on August 10, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals Inc is a biotechnology company. It is engaged in the research and development of small molecule drugs for infectious diseases. The Company uses its chemistry-driven approach & drug discovery capabilities to develop its products.
Sector
Healthcare
Industry
Biotechnology